RE:RE:RE:RE:RE:RE:CD8+ TiLs and T-cell exhaustionFor tthose traders who are trying to exploit the BRACELET-1 cohort 3 results by implying something that is not .. cohort 3 involved the immune checkpoint inhibitor avelumab which is the only PD-(L)1 inhibitor with an intact Fc component, thus precluding this ICI's effectiveness. Other ICIs like atezolizumab or pembrolizumab, foe example, have the Fc component inactived, and more effective than avelumab. In contrast to cohort 3, cohort 2 using pelareorep + paclitaxel significantly expanded on pre-existing and new T cell clones, and will be the doublet used in ONCY's registrational brest cancer study. So no worries ... ONCY is demonstrating that pelareorep is an effective agent in the pelareorep + paclitaxel combo when compared to the control, namely paclitaxel alone.